Bayer achieved revenue of 22.9 billion euros in the first half of the year, and its business in China was affected by the volume of purchases!

Read: On August 4, Bayer reported its second quarter 2020 results: Group sales of EUR 10,054 million, down 2.5% YoY. on August 4,
, Bayer reported its second quarter 2020 results: Group sales of EUR 10,054 million, down 2.5% Year-on-Year.
crop science business continued to perform strongly in the second quarter, with sales of the pharmaceutical and consumer health businesses declining, mainly due to the GLOBAL OUTBREAK OF COVID-19 and China's Volume Purchasing Policy.
specifically, sales of the crop science business were EUR 4.802 billion, up 3.2% YoY, while sales in the pharmaceutical business were EUR 3,992 million, down 8.8% YoY, and sales of the consumer health business were EUR 1.201 billion, down 1.9% YoY.
Core Earnings per Share (EPS) was 1.59 euros, an increase of 5.3%.
Despite the COVID-19 pandemic and associated uncertainty, Bayer's business achieved solid results in the first half of the year: Group sales of EUR 22.899 billion (up 8.4 per cent), including EUR 11.636 billion (up 4.6 per cent), the pharmaceutical business of EUR 8.538 billion (down 2.5 per cent), and the consumer health business of EUR 2.599 billion (up 5.7 per cent).
Core EPS was 4.26 euros, an increase of 8.1%.
notable, Bayer has a net loss of 8,059 million euros as a result of the litigation left over from the acquisition of Monsanto.
in the first half of this year, due to the prevalence of COVID-19, exposure restrictions and protective measures around the world led to a reduction in hospital selection of treatment, some treatment was delayed.
this particularly affected sales of women's health, ophthalmology, radiation and other products, until the second quarter of a slight recovery trend.
in China, business has again been hampered by a significant reduction in the price of generic products due to the implementation of the sourcing policy.
sales of specific products in the second quarter, sales of oral anticoagulant Xarelto were EUR 1,057 million, up 6.8% YoY, mainly due to increased sales in China, Russia and Germany.
the growth of the anti-cancer drug Stivarga (129 million euros, or 24.8 percent) and the pulmonary arterial high-pressure drug Adempas (125 million euros, or 23.6 percent) was particularly strong, with demand for both products increasing in every market, particularly in the United States.
in China, sales of Stivarga are also rising rapidly. sales of the
ophthalmology drug Eylea decreased by 6.4% to EUR 568 million, mainly due to a decrease in the number of treatments, partially offset by the listing of Eylea prefilled syringes in Europe and Japan, as well as the increase in total capacity in the Japanese market.
notable, sales of anti-VEGF inhibitor Lucentis, an eye competition from Roche and Novartis, fell 25 percent over the same period.
, eylea's sales performance remains strong.
COVID-19 pandemic also led to a significant decline in the Mirena/Kyleena/Jaydes intrauterine system (EUR 185 million, -37.0%).
a sharp decline in revenue from select-term treatment, especially in the United States.
diabetes drug Glucobay sales fell 73.8 percent, mainly due to China's band purchase policy, which was not offset by the resulting surge in volume.
Bayer noted that the impact of the COVID-19 pandemic on the company's full-year results remains unpredictable.
therefore, the financial indicators issued in February 2020 were adjusted on the basis of the business development in the first half of the year and the uncertainties involved in the second half of the year: exchange rate-adjusted group sales of 43-44 billion euros (previously EUR 44-45 billion) were equivalent to a 0-1% increase on a currency and portfolio adjustment basis;
Source: 1, Bayer: Solid and Despite COVID-19 impact2, Bayer's Eylea shows pandemic ei vawwydde, but major China price cut drags on business.